Efficacy of Rituximab Outlasts B-Cell Repopulation in Multiple Sclerosis: Time to Rethink Dosing?
Journal
Neurology(R) neuroimmunology & neuroinflammation
ISSN: 2332-7812
Titre abrégé: Neurol Neuroimmunol Neuroinflamm
Pays: United States
ID NLM: 101636388
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
23
01
2023
accepted:
05
07
2023
medline:
23
8
2023
pubmed:
22
8
2023
entrez:
21
8
2023
Statut:
epublish
Résumé
Patients with multiple sclerosis (PwMS) receiving extended dosing of rituximab (RTX) have exhibited no return of disease activity, which suggests that maintenance of deep depletion of circulating B cells is not necessary to maintain the efficacy of RTX in MS. This was a prospective monocentric observational study including all consecutive PwMS who started or continued RTX after 2019, when the medical staff decided to extend the dosing interval up to 24 months for all patients. Circulating B-cell subsets were monitored regularly and systematically in case of relapse. The first extended interval was analyzed. We included 236 PwMS (81% with relapsing-remitting MS; mean [SD] age 43 [12] years; median [range] EDSS score 4 [0-8]; mean relapse rate during the year before RTX start 1.09 [0.99]; 41.5% with MRI activity). The median number of RTX infusions before extension was 4 (1-13). At the time of the analysis, the median delay in dosing was 17 months (8-39); the median proportion of circulating CD19 The efficacy of RTX outlasted substantial reconstitution of circulating B cells in PwMS, which suggests that renewal of the immune system underlies the prolonged effect of RTX in MS. These findings suggest that extended interval dosing of RTX that leads to a significant reconstitution of circulating B cells is safe in PwMS, could reduce the risk of infection, and could improve vaccine efficacy.
Sections du résumé
BACKGROUND AND OBJECTIVES
Patients with multiple sclerosis (PwMS) receiving extended dosing of rituximab (RTX) have exhibited no return of disease activity, which suggests that maintenance of deep depletion of circulating B cells is not necessary to maintain the efficacy of RTX in MS.
METHODS
This was a prospective monocentric observational study including all consecutive PwMS who started or continued RTX after 2019, when the medical staff decided to extend the dosing interval up to 24 months for all patients. Circulating B-cell subsets were monitored regularly and systematically in case of relapse. The first extended interval was analyzed.
RESULTS
We included 236 PwMS (81% with relapsing-remitting MS; mean [SD] age 43 [12] years; median [range] EDSS score 4 [0-8]; mean relapse rate during the year before RTX start 1.09 [0.99]; 41.5% with MRI activity). The median number of RTX infusions before extension was 4 (1-13). At the time of the analysis, the median delay in dosing was 17 months (8-39); the median proportion of circulating CD19
DISCUSSION
The efficacy of RTX outlasted substantial reconstitution of circulating B cells in PwMS, which suggests that renewal of the immune system underlies the prolonged effect of RTX in MS. These findings suggest that extended interval dosing of RTX that leads to a significant reconstitution of circulating B cells is safe in PwMS, could reduce the risk of infection, and could improve vaccine efficacy.
Identifiants
pubmed: 37604695
pii: 10/5/e200152
doi: 10.1212/NXI.0000000000200152
pmc: PMC10442066
pii:
doi:
Substances chimiques
Rituximab
4F4X42SYQ6
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
Nat Rev Neurol. 2021 Jul;17(7):399-414
pubmed: 34075251
Ann Neurol. 2008 Mar;63(3):395-400
pubmed: 18383069
Neurol Neuroimmunol Neuroinflamm. 2021 Mar 15;8(3):
pubmed: 33722933
Ann Neurol. 2010 Apr;67(4):452-61
pubmed: 20437580
JAMA Neurol. 2013 Sep 1;70(9):1110-7
pubmed: 23897062
Neurol Neuroimmunol Neuroinflamm. 2020 Aug 4;7(5):
pubmed: 32753406
Front Immunol. 2021 Dec 22;12:773853
pubmed: 35003091
Neurol Neuroimmunol Neuroinflamm. 2022 Nov 21;10(1):
pubmed: 36411076
Arthritis Rheumatol. 2019 Nov;71(11):1812-1823
pubmed: 31131994
N Engl J Med. 2017 Jan 19;376(3):221-234
pubmed: 28002679
JAMA Neurol. 2020 Feb 1;77(2):184-191
pubmed: 31589278
JAMA Netw Open. 2018 Nov 2;1(7):e184169
pubmed: 30646343
Mult Scler. 2022 Jun;28(7):1121-1125
pubmed: 34240631
Mult Scler J Exp Transl Clin. 2021 Nov 29;7(4):20552173211062142
pubmed: 34925877
Neurology. 2016 Jul 12;87(2):141-7
pubmed: 27316241
Nat Rev Neurol. 2020 Jan;16(1):56-62
pubmed: 31649335
ACR Open Rheumatol. 2019 Aug 27;1(8):527-532
pubmed: 31777835
J Neurol Neurosurg Psychiatry. 2022 Sep;93(9):986-994
pubmed: 35688629
J Neurol. 2019 Jan;266(1):57-67
pubmed: 30377816
J Clin Invest. 2012 Apr;122(4):1393-402
pubmed: 22426210
J Neurol. 2021 Jun;268(6):2161-2168
pubmed: 33475825
Mult Scler. 2022 Nov;28(13):2106-2111
pubmed: 35735030
Clin Exp Immunol. 2010 Nov;162(2):271-9
pubmed: 20854328
N Engl J Med. 2008 Feb 14;358(7):676-88
pubmed: 18272891
Neurol Neuroimmunol Neuroinflamm. 2021 Jul 14;8(5):
pubmed: 34261812
Neurol Neuroimmunol Neuroinflamm. 2021 Nov 23;9(1):
pubmed: 34815322
Arthritis Rheum. 2010 Jan;62(1):75-81
pubmed: 20039396
J Neurol Neurosurg Psychiatry. 2019 Apr;90(4):486-487
pubmed: 29929977
EBioMedicine. 2021 Oct;72:103581
pubmed: 34563483
Sci Transl Med. 2015 Oct 21;7(310):310ra166
pubmed: 26491076
Ann Neurol. 2020 Feb;87(2):256-266
pubmed: 31725931
Blood. 2008 Aug 15;112(4):1147-50
pubmed: 18375792
Proc Natl Acad Sci U S A. 2018 Sep 25;115(39):9773-9778
pubmed: 30194232
Mult Scler Relat Disord. 2020 Sep;44:102279
pubmed: 32645640
Mult Scler Relat Disord. 2022 Apr;60:103719
pubmed: 35276450
Neurol Neuroimmunol Neuroinflamm. 2020 Jun 25;7(5):
pubmed: 32587103
Int J Hematol. 2020 Sep;112(3):422-426
pubmed: 32342335
Mult Scler Relat Disord. 2020 Jan;37:101468
pubmed: 31683231
Blood. 2002 Sep 15;100(6):2257-9
pubmed: 12200395
J Exp Med. 2012 May 7;209(5):1001-10
pubmed: 22547654
Ann Neurol. 2021 Apr;89(4):780-789
pubmed: 33480077
Arthritis Rheum. 2006 Aug;54(8):2377-86
pubmed: 16869000
Neurology. 2016 Nov 15;87(20):2074-2081
pubmed: 27760868